Valuation: IDEAYA Biosciences, Inc.

Market Cap 3.83B 3.28B 3.07B 2.81B 5.27B 366B 5.34B 36.25B 14.14B 184B 14.37B 14.06B 609B P/E 2026 *
-8.59x
P/E 2027 * -9.43x
Enterprise Value 2.84B 2.43B 2.27B 2.08B 3.91B 271B 3.96B 26.86B 10.47B 136B 10.65B 10.42B 451B EV / Sales 2026 *
72.1x
EV / Sales 2027 * 23.9x
Free-Float
97.81%
Yield 2026 *
-
Yield 2027 * -
1 day+1.43%
1 week+9.28%
Current month+11.75%
1 month+13.34%
3 months+36.32%
6 months+24.05%
Current year+14.75%
1 week 35.8
Extreme 35.8
40.56
1 month 34.56
Extreme 34.56
40.56
Current year 26.81
Extreme 26.81
40.58
1 year 23.23
Extreme 23.23
40.58
3 years 13.45
Extreme 13.45
47.74
5 years 8.14
Extreme 8.14
47.74
10 years 2.95
Extreme 2.95
47.74
Manager TitleAgeSince
Chief Executive Officer 51 2015-05-31
Director of Finance/CFO 51 2025-04-30
Chief Tech/Sci/R&D Officer 59 2022-11-20
Director TitleAgeSince
Chairman 51 2026-06-16
Chairman 67 -
Director/Board Member 71 2015-09-30
Date Insider Type Main position Quantity % Market Cap.
7/7/26 Fiscal year

Controller/Auditor

28,650 0.0327%
6/16/26 Free

Director

20,000 0.0228%
1/30/26 Free

Founder

600,000 0.6846%
Change 5-day change 1-year change 3-year change Capi.($)
+1.43%+9.28%+57.92%+41.93% 3.83B
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average +0.55%+4.92%+80.30%+116.94% 28.03B
Weighted average by Cap. +0.50%+4.78%+98.97%+144.78%

Financials

2026 *2027 *
Net sales 39.36M 33.71M 31.54M 28.88M 54.19M 3.77B 54.91M 373M 145M 1.89B 148M 145M 6.26B 115M 98.93M 92.57M 84.73M 159M 11.05B 161M 1.09B 426M 5.55B 434M 424M 18.36B
Net income -432M -370M -346M -317M -595M -41.34B -603M -4.09B -1.6B -20.77B -1.62B -1.59B -68.68B -421M -361M -338M -309M -580M -40.3B -588M -3.99B -1.56B -20.24B -1.58B -1.55B -66.95B
Net Debt -991M -849M -794M -727M -1.36B -94.84B -1.38B -9.39B -3.66B -47.64B -3.72B -3.64B -158B -1.07B -914M -855M -783M -1.47B -102B -1.49B -10.11B -3.94B -51.3B -4.01B -3.92B -170B
Logo IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
Employees
145
Date Price Change Volume
26-08-21 US$39.67 +1.43% 860,570
26-08-20 US$39.11 +0.62% 1,634,020
26-08-19 US$38.87 +2.48% 931,923
26-08-18 US$37.93 +3.80% 629,485
26-08-17 US$36.54 +0.66% 427,842
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
39.67USD
Average target price
52.15USD
Spread / Average Target
+31.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDYA Stock